Change to Licensing Type | JAMA Oncology | JAMA Network
[Skip to Navigation]
Sign In
Views 372
Citations 0
Correction
June 25, 2020

Change to Licensing Type

JAMA Oncol. 2020;6(9):1473. doi:10.1001/jamaoncol.2020.2873

In the Original Investigation titled “Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial,”1 published online May 29, 2020, there was a change made to the license type from standard to open access. This article was corrected online.

References
1.
Choueiri  TK, Heng  DYC, Lee  JL,  et al.  Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial.   JAMA Oncol. Published online May 29, 2020. doi:10.1001/jamaoncol.2020.2218PubMedGoogle Scholar
×